Annual Report for the year ended 30 June 2023

MGC Pharmaceuticals Limited

29 September 2023

 

MGC Pharmaceuticals Ltd.

Annual Report for the year ended 30 June 2023

and ASX Corporate Governance Statement

29 September 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to provide the following documents in respect of the financial year ended 30 June 2023:

·      Annual Financial Report (Audited)

A copy of the Company's Annual Financial Report for the year ended 30 June 2023 can be found at the following URL:
https://www.investi.com.au/api/announcements/mxc/afa2a099-b57.pdf

·      ASX Appendix 4G "Key disclosures - Corporate Governance Council Principles and Recommendations" and MGC Pharma's Corporate Governance Statement

A copy of the Company's ASX Appendix 4G - Corporate Governance Disclosures & Corporate Governance Statement can be found at the following URL:

https://www.investi.com.au/api/announcements/mxc/7516e7d4-208.pdf

-Ends-

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd      Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END